Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
PSA level assessed for at least 3 months after RP may minimize overtreatment, and in this study, a higher persistent PSA level was associated with a worse prognosis.
Authors
- Bruce J. Trock (ORCID: https://orcid.org/0000-0003-3529-9295)
- Derya Tilki (ORCID: https://orcid.org/0000-0001-7033-1380)
- Jing Wu (ORCID: https://orcid.org/0000-0001-7808-6981)
- Anthony V. D’Amico
- Hartwig Huland (ORCID: https://orcid.org/0000-0002-4237-9480)
- Misop Han (ORCID: https://orcid.org/0009-0006-7797-3080)
- Ming‐Hui Chen
- Markus Graefen
Institutions
- Brigham and Women's Hospital (US)
- Koç University (TR)
- University of Connecticut (US)
- Johns Hopkins University (US)
- Universität Hamburg (DE)
- University of Rhode Island (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1001/jamaoncol.2025.0110
- Citations
- 10
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 15.18